MacroGenics, Inc. (NASDAQ:MGNX – Get Rating) has earned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among […]
HC Wainwright restated their buy rating on shares of MacroGenics (NASDAQ:MGNX – Get Rating) in a research note published on Monday morning, Benzinga reports. The brokerage currently has a $14.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MacroGenics’ Q1 2023 earnings at $1.44 EPS and FY2023 earnings at $0.08 […]
HC Wainwright restated their buy rating on shares of MacroGenics (NASDAQ:MGNX – Get Rating) in a research note issued to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $14.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MacroGenics’ Q1 2023 earnings at $1.44 EPS and FY2023 earnings […]
MacroGenics (NASDAQ:MGNX – Get Rating)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $14.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 88.17% from the company’s current price. MGNX […]
MacroGenics (NASDAQ:MGNX – Get Rating) had its price target lifted by Citigroup from $7.00 to $8.00 in a research note released on Monday, The Fly reports. Several other research firms have also weighed in on MGNX. Guggenheim reissued a neutral rating on shares of MacroGenics in a research note on Friday, March 17th. Cowen lowered […]